TL;DR
The "numbers game" is real, but the lever is cycle count, not drug dose. My follicle pool that month is fixed — pumping FSH from 300 → 450 IU adds zero eggs in three head-to-head trials. Real movers for my profile: dual trigger (~2.5× live birth in poor responders), CoQ10 600 mg/day for 60+ days (~1.8× clinical pregnancy in DOR), 3 cycles instead of 2. Real harms: OCP-primed antagonist protocol (~25% lower live birth in Cochrane). Things that sound impressive but recent trials zeroed out: testosterone pretreatment, growth hormone, DHEA. DuoStim is now mainstream technique but not proven better than two sequential cycles — my instinct to skip is supported.
What to do
- Bump CoQ10 to 600 mg/day right now. 200 mg three times daily, ubiquinol form, for at least 60 days before each retrieval. Best-evidenced supplement for diminished ovarian reserve — roughly doubles oocyte yield in the strongest trial and cuts miscarriage risk by ~60% in pooled data. Cycle 1 will only get ~5 weeks; cycles 2 and 3 will get the full window.
- Confirm dual trigger with Repromeda. Wasn't discussed in the May 7 doctor consult — needs to be asked at the May 25 visit. In women with my profile (Bologna poor responders, POSEIDON group 4), dual trigger lifts live birth roughly 2.5× vs hCG alone. Reprofit's plan had it; Repromeda's hasn't confirmed yet.
- Push for total FSH ≤300 IU. Three RCTs say 450 and 600 IU add zero eggs vs 300. ESHRE 2025 makes a Strong recommendation against going above 300 in patients like me. Repromeda's plan is Pergoveris + Gonal-F (FSH+LH combo) — confirm the combined daily FSH stays at or below 300 IU at the May 25 visit.
- Push for luteal estradiol priming. Oral E2 starting day 21–22 of the prior cycle. Cuts cycle cancellation ~40% and raises clinical pregnancy ~33% in poor responders. Dr. Filková mentioned this as one option on the menu at the May 7 consult — make it explicit rather than implicit. Could be the most impactful tweak if cycle 1 disappoints.
- Commit to 3 retrievals, not 2. My CLBR research already showed cycle 3 is where the curve is still climbing steeply (~25% cumulative). Adding a 3rd cycle moves my odds more than any within-cycle adjustment.
What to avoid
- Don't accept OCP priming with an antagonist protocol. Most consistent "harm" signal in the priming literature — ~25% lower live birth in Cochrane meta-analysis. If a clinic suggests it for scheduling convenience, ask for luteal estradiol priming instead.
- Skip testosterone pretreatment. Older meta-analyses were positive, but the 2023 T-TRANSPORT trial (the largest, most rigorous — 290 women, placebo-controlled, double-blind, 10 centers) found zero benefit on pregnancy or oocyte count. Numerically fewer embryos with testosterone.
- Skip growth hormone. $800–2500 per cycle. Best RCT (LIGHT, 2019) showed identical live birth rates with vs without. Largest IVF GH trial ever (Mourad 2024) — same result.
- Skip DHEA. Cochrane 2024 verdict: "likely little to no difference" in live birth. The UK regulator gives it the black rating ("no effect on live birth"). Was in heavier rotation 5–10 years ago; the rigorous trials didn't replicate the early enthusiasm.
- Skip DuoStim unless a clinic makes a compelling case. Two stims in one menstrual cycle. The best RCT (BISTIM, 2023) found no oocyte advantage and numerically lower live birth vs two sequential cycles. Main proven benefit is calendar speed — not a constraint for me with the 6-month window.
- Skip letrozole adjunct during stim. ESHRE 2025 "probably not recommended" for poor responders. Reduces drug cost but no live-birth signal.
- Skip acupuncture for outcomes. Cochrane review: no effect on live birth. Fine if it helps emotionally; don't pay for it expecting an outcome benefit.
Levers at a glance
| Lever | More eggs? | Better quality? | What to do |
|---|
| 3 cycles vs 2 | Yes, big | N/A | Commit to 3 |
| FSH 300 → 450 IU | No | Maybe worse at very high total dose | Stay at 300 |
| Pergoveris / Meriofert (LH-add) | Neutral | Modestly better in late 30s | Already in plan |
| Long agonist vs antagonist protocol | Same | Same LBR in poor responders | Repromeda is leaning long — defensible (better follicle sync) |
| Mild stim (≤150 IU) | ~1–2 fewer | Same | Skip — conventional is better for AFC ≥3 |
| DuoStim | No advantage vs 2 sequential | Same as standard | Skip |
| Dual trigger (hCG + agonist) | Yes | ~2.5× live birth | Keep in every cycle |
| Luteal estradiol priming | −40% cancellation | +33% clinical preg | Ask clinics — strongest cycle-2 tweak |
| OCP priming + antagonist | Same | ~25% lower live birth | AVOID |
| PPOS (progestin) priming | Same | Same | Acceptable, no upside |
| Letrozole during stim | Mixed | None | Skip |
| CoQ10 600 mg/day × 60d | +1–2 eggs | ~1.8× clinical preg, fewer miscarriages | Start today |
| Melatonin 3 mg nightly | Modest | Better embryos, no LB signal | Reasonable add |
| Testosterone pretreatment | None | None | Skip (T-TRANSPORT 2023) |
| DHEA | +0.6 eggs | None | Skip |
| Growth hormone | +1 egg | None on live birth | Skip — expensive, no outcome |
| Alcohol <4 drinks/week | — | +16% live birth vs heavier | Abstain stim → transfer |
| Vitamin D ≥30 ng/mL | — | Replete > deficient | Test, correct if low |
| Acupuncture | None | None | Optional, not therapeutic |
What this means for my 3-cycle plan
Current plan is Repromeda — long protocol with Pergoveris + Gonal-F, sequential monthly cycles, no DuoStim. Long-vs-antagonist is a wash on outcomes in poor responders, and Dr. Filková's reasoning (long protocol synchronizes follicle sizes better, addressing the mixed-size issue I had at Grace) is sound. Three open items to raise at the May 25 visit: (1) confirm dual trigger; (2) confirm total FSH ≤300 IU; (3) push for luteal estradiol priming, which she already mentioned as one option. Start CoQ10 600 mg/day today regardless of which clinic. Skip the expensive-and-trendy adjuvants (testosterone, GH, DHEA). The single biggest lever I have is non-protocol: finishing all 3 retrievals inside the window instead of stopping at 2. If I pivot to another clinic before May 25, the protocol-specific lines above will need re-checking against that clinic's plan.
Caveats
- I'm at age 40 exactly — the upper edge of where LH-add evidence is strongest (35–40). Effect "diminishes" at ≥40 per the meta-analysis authors. Still defensible, not slam-dunk.
- CoQ10 trials are mostly Chinese and unblinded. I'm willing to take that bet because it's $30/month and side-effect free, but the evidence isn't airtight.
- None of this overrides the cumulative LBR ceiling. Adjuvants and protocol tweaks shift odds at the margin. They don't reverse age 40 / AMH 1.30 biology.